Management ChangeJun 2, 2026, 09:06 AM
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
AI Summary
Kazia Therapeutics Limited announced the appointment of James Levine as its new Chief Financial Officer, effective June 1, 2026. Mr. Levine brings over two decades of experience in investment banking, executive, and financial leadership roles at publicly traded biotech companies, including Cardiff Oncology and Cidara Therapeutics. His compensation package includes an annual base salary of US$475,000, an annual target bonus of 40% of his base salary, and options over 200,000 American Depositary Shares, with specific severance provisions.
Key Highlights
- Kazia Therapeutics appointed James Levine as Chief Financial Officer, effective June 1, 2026.
- Mr. Levine will receive an annual base salary of US$475,000.
- He is eligible for an annual target bonus of 40% of his base salary, prorated for 2026.
- Subject to Board approval, Mr. Levine will be granted options over 200,000 American Depositary Shares (ADSs).
- One-third of ADS options vest upon employment commencement, with the remainder vesting in equal yearly installments.
- Severance includes 12 months base salary and pro-rata bonus for termination without Cause or resignation for Good Reason in connection with a Change in Control.
- Severance includes up to 6 months base salary and pro-rata bonus for termination without Cause or resignation for Good Reason not in connection with a Change in Control.
- Mr. Levine previously served as CFO of Cardiff Oncology and Cidara Therapeutics, and was a Managing Director at Goldman Sachs & Co.
Price Impact
More from KZIA